{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:36:13Z","timestamp":1775032573120,"version":"3.50.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To ensure adequate preparedness of immunocompromised populations for future pandemic waves, it is crucial to assess the humoral immune response of people living with HIV (PLWH) to existing vaccination strategies and major Omicron sublineages following BA.5\/BF.7 breakthrough infection (BTI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study enrolled 232 PLWH who had received either the CoronaVac\/BBIBP-CorV or ZF2001 vaccine and experienced the BA.5\/BF.7 wave in China between January and April 2023. Serum samples from each individual were collected approximately 1\u20136\u202fmonths after the last exposure. Immunoglobulin G (IgG) and total antibodies against SARS-CoV-2 were measured using a chemiluminescent immunoassay. Neutralizing antibodies (NAbs) against D614G, BA.5, and XBB.1.5 were detected using a pseudovirus-based neutralization assay. Meanwhile, an Enterprise WeChat link was created to allow PLWH to self-report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and clinical symptoms associated with coronavirus disease 2019 (COVID-19).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The Omicron BA.5\/BF.7 BTI rate among PLWH was 76.7%. The most commonly reported symptoms were fever, fatigue, and muscle ache. PLWH who experienced BA.5\/BF.7 BTI after three doses of inactivated vaccines showed elevated levels of total antibodies, IgG, and NAb titers against D614G and BA.5. In contrast, those who experienced BTI after three doses of ZF2001 vaccines showed the highest NAb titers against D614G and BA.5. However, the neutralizing capacity of antibodies against XBB.1.5 was significantly reduced in both study cohorts. PLWH who had CD4 lymphocyte counts greater than 500 cells\/\u03bcL demonstrated higher NAb titers against all tested variants and reported a lower incidence of symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Hybrid immunity resulting from vaccination and BA.5\/BF.7 BTI enhances humoral immune responses in PLWH, which may contribute to improved protection against COVID-19. However, this hybrid immunity offers limited protection against Omicron variant XBB.1.5. Regular monitoring of immune responses to new vaccines targeting emerging variants is crucial for optimizing COVID-19 prevention strategies in PLWH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmicb.2026.1803277","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:42:43Z","timestamp":1775022163000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Humoral immunity and infection status of PLWH following vaccination after the BA.5\/BF.7 wave"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuchen","family":"Xie","sequence":"first","affiliation":[{"name":"School of Public Health, North China University of Science and Technology","place":["Tangshan, China"]},{"name":"Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, North China University of Science and Technology","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuedong","family":"Song","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, North China University of Science and Technology","place":["Shijiazhuang, Hebei, China"]},{"name":"Department of Laboratory Medicine, Handan Central Hospital, Hebei Medical University","place":["Handan, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, North China University of Science and Technology","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijing","family":"Wang","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, North China University of Science and Technology","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huixia","family":"Gao","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, North China University of Science and Technology","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, North China University of Science and Technology","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Feng","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, North China University of Science and Technology","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"Jingmen Central Hospital","place":["Jingmen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Yan","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, North China University of Science and Technology","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumin","family":"Feng","sequence":"additional","affiliation":[{"name":"Hebei Coordinated Innovation Center of Occupational Health and Safety, School of Public Health, North China University of Science and Technology","place":["Tangshan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erhei","family":"Dai","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, North China University of Science and Technology","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuling","family":"Wang","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, North China University of Science and Technology","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aidong","family":"Feng","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, North China University of Science and Technology","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"100926","DOI":"10.1016\/j.nmni.2021.100926","article-title":"SARS-CoV-2 reinfection in patients negative for immunoglobulin G following recovery from COVID-19","volume":"43","author":"Ali","year":"2021","journal-title":"New Microbes New Infect."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12877-023-04494-w","article-title":"Clinical characteristics and outcomes of COVID-19 patients with preexisting dementia: a large multicenter propensity-matched Brazilian cohort study","volume":"24","author":"Bicalho","year":"2024","journal-title":"BMC Geriatr."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1093\/infdis\/jiad311","article-title":"COVID-19 outcomes among people with HIV and COVID-19 in New York City","volume":"228","author":"Braunstein","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.3390\/nu15224727","article-title":"Exploring the association between delirium and malnutrition in COVID-19 survivors: a geriatric perspective","volume":"15","author":"Damanti","year":"2023","journal-title":"Nutrients"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2174\/011570162x277788231128111517","article-title":"Factors associated with fatal COVID-19 outcomes among people living with HIV: a cohort study","volume":"21","author":"Drobyshevskaya","year":"2023","journal-title":"Curr. HIV Res."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e00820","DOI":"10.1128\/aac.00825-20","article-title":"Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and proinflammatory cytokine production","volume":"64","author":"Fintelman-Rodrigues","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.46234\/ccdcw2023.070","article-title":"Effectiveness of COVID-19 vaccination against SARS-CoV-2 omicron variant infection and symptoms - China, December 2022-February 2023","volume":"5","author":"Fu","year":"2023","journal-title":"China CDC Weekly"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e0234765","DOI":"10.1371\/journal.pone.0234765","article-title":"The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries","volume":"15","author":"Grant","year":"2020","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e29143","DOI":"10.1002\/jmv.29143","article-title":"CoronaVac and BBIBP-CorV vaccines against SARS-CoV-2 during predominant circulation of omicron BA.5.2 and BF.7 in China, a retrospective cohort study","volume":"95","author":"Hu","year":"2023","journal-title":"J. Med. Virol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e0273712","DOI":"10.1371\/journal.pone.0273712","article-title":"Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan","volume":"17","author":"Ishizaki","year":"2022","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"104986","DOI":"10.1016\/j.jcv.2021.104986","article-title":"Dynamics of IgG-avidity and antibody levels after COVID-19","volume":"144","author":"L\u00f6fstr\u00f6m","year":"2021","journal-title":"J. Clin. Virol."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"104058","DOI":"10.1016\/j.archger.2020.104058","article-title":"Clinical characteristics of older patients infected with COVID-19: a descriptive study","volume":"89","author":"Niu","year":"2020","journal-title":"Arch. Gerontol. Geriatr."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/hiv.13578","article-title":"HIV disease metrics and COVID-19 infection severity and outcomes in people living with HIV in central and eastern Europe","volume":"25","author":"Oprea","year":"2024","journal-title":"HIV Med."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e28497","DOI":"10.1002\/jmv.28497","article-title":"Nirmatrelvir-ritonavir therapy and COVID-19 vaccination improve clinical outcomes of SARS-CoV-2 omicron variant infection","volume":"95","author":"Qi","year":"2023","journal-title":"J. Med. Virol."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"873596","DOI":"10.3389\/fpubh.2022.873596","article-title":"The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: a systematic review and meta-analysis","volume":"10","author":"Rahmani","year":"2022","journal-title":"Front. Public Health"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2024.08.009","article-title":"Prevalence of infection and reinfection among health care workers in a hospital of northern China between BA.5\/BF.7 and XBB.1.5 wave","author":"Song","year":"2024","journal-title":"Am. J. Infect. Control"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e0291670","DOI":"10.1371\/journal.pone.0291670","article-title":"Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination","volume":"18","author":"Takahashi","year":"2023","journal-title":"PLoS One"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2174\/011570162x282739231222062830","article-title":"The interrelationship between HIV infection and COVID-19: a review of the literature","volume":"22","author":"Wang","year":"2024","journal-title":"Curr. HIV Res."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2249121","DOI":"10.1080\/22221751.2023.2249121","article-title":"Neutralization against omicron subvariants after BA.5\/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination","volume":"12","author":"Wang","year":"2023","journal-title":"Emerg. Microbes Infect."},{"key":"ref20","volume-title":"COVID-19 Weekly Epidemiological Update, edition 146, 8 June 2023","year":"2023"},{"key":"ref21","volume-title":"COVID-19 Epidemiological Update, edition 172, 19 October 2024","year":"2024"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"746","DOI":"10.3390\/v14040746","article-title":"COVID-19 in elderly, immunocompromised or diabetic patients-from immune monitoring to clinical management in the hospital","volume":"14","author":"W\u00fcnsch","year":"2022","journal-title":"Viruses"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e067095","DOI":"10.1136\/bmjopen-2022-067095","article-title":"COVID-19 vaccine effectiveness among people living with and without HIV in South Carolina, USA: protocol of a population-based cohort study","volume":"12","author":"Xueying","year":"2022","journal-title":"BMJ Open"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e38382","DOI":"10.1016\/j.heliyon.2024.e38382","article-title":"Epidemiological and immunological characteristics of middle-aged and elderly people in housing estates after omicron BA.5 wave in Jinan, China","volume":"10","author":"Zhao","year":"","journal-title":"Heliyon"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e29640","DOI":"10.1002\/jmv.29640","article-title":"Epidemiological characteristics and antibody kinetics of elderly population with booster vaccination following both omicron BA.5 and XBB waves in China","volume":"96","author":"Zhao","year":"","journal-title":"J. Med. Virol."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"112075","DOI":"10.1016\/j.celrep.2023.112075","article-title":"Durability of neutralization against omicron subvariants after vaccination and breakthrough infection","volume":"42","author":"Zhu","year":"2023","journal-title":"Cell Rep."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1803277\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:42:44Z","timestamp":1775022164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1803277\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":26,"alternative-id":["10.3389\/fmicb.2026.1803277"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1803277","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"1803277"}}